If you’ve recently received a US patent, you may have noticed a glossy ceremonial copy in your mailbox. But starting March 9, 2026, that keepsake will only arrive if you ask for it. The US Patent and Trademark Office (USPTO) is changing how it handles ceremonial copies of electronic patent grants Continue Reading
Highlights and Shortfalls of Recent PBM Legislation
There have been a series of court cases and federal legislation targeting the spread pricing model often used by pharmacy benefit managers (PBM). Spread pricing involves two points of time in prescription drug transactions. First, PBMs negotiate discounts with manufacturers for prescription drugs Continue Reading
One Month of Indiana’s Consumer Data Privacy Law . . . Where Do You Stand on Compliance?
Enforcement of the Indiana Consumer Data Protection Act (CDPA) has begun, and its penalties can add up quickly. The CDPA was signed in 2023 and became effective January 1, 2026. The law governs how covered businesses collect, use, disclose, store, and analyze “personal data,” i.e., nonpublic Continue Reading
FDA Modernizes Draft Guidance on Statistical Methods to Support Clinical Trial Data
Consistent with the Food and Drug Administration’s (FDA) commitment to streamlining the prescription drug and biologics approval processes by adopting innovative approaches to clinical trial design, the agency recently published its draft guidance for industry, “Use of Bayesian Methodology in Continue Reading
Abusive Images Are Posted on an Online Platform—Now What?
A horrific new story hits our feeds every day. Social media platforms and other online spaces are drowning in a flood of abusive generative artificial intelligence (GenAI) content. Like with anything on the internet, users are creating a broad range of content, from entertaining to endearing and Continue Reading
Will Streamlined Patent Claims Lead to Streamlined Examination? For Now, the Patent Office Says Yes
The patent examination process can often take far too long, and the United States Patent and Trademark Office (USPTO) is determined to do something about it in 2026. This past October, the USPTO started a one-year pilot program to expedite the patent examination process for patent applications with Continue Reading
Compliance Note No. 15: 2025 NJ Lobbying Reporting Requirements
Organizations, including partnerships, corporations, committees, associations, trade associations, and labor unions that spent more than $2,500 on lobbying activities in New Jersey in 2025 are required to file a report with the New Jersey Election Law Enforcement Commission (ELEC) no later than Continue Reading
New Jersey Amends Family Leave Act to Broaden Eligibility, Adds Certain Job Restoration Rights To TDI/NJFLI Laws
In one of his last acts in office, now-former Governor Phil Murphy signed legislation on January 17, 2026, that amends the New Jersey Family Leave Act (NJFLA) to expand its coverage to smaller employers. As a reminder, the NJFLA provides eligible employees with up to 12 weeks of job-protected leave Continue Reading
New Jersey Enacts Psilocybin Behavioral Health Access and Therapy Pilot Program
Governor Phil Murphy signed into law Senate Bill No. 2283 (2R), establishing the Psilocybin Behavioral Health Access and Therapy Pilot Program (the Pilot Program). The legislation appropriates $6 million and positions New Jersey as the latest state to formally explore regulated access to Continue Reading
2026 Updates to US Merger Filing Thresholds, Filing Fees, and Interlocking Directorate Exemptions
On January 14, 2026, the Federal Trade Commission (FTC) announced increased reporting thresholds for transactions. Annually, the FTC reviews and adjusts the premerger notification thresholds for reporting acquisitions of voting securities, assets, or noncorporate interests (each a transaction) under Continue Reading